Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)
A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Rajasthan、インド、334003
- Novartis Investigative Site
-
-
Delhi
-
New Delhi、Delhi、インド、110029
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad、Gujarat、インド、380054
- Novartis Investigative Site
-
Vadodara、Gujarat、インド、390022
- Novartis Investigative Site
-
-
Maharashtra
-
Nagpur、Maharashtra、インド、440010
- Novartis Investigative Site
-
Nagpur、Maharashtra、インド、440012
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、インド、600101
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad、Telangana、インド、500082
- Novartis Investigative Site
-
-
-
-
-
Singapore、シンガポール、169609
- Novartis Investigative Site
-
Singapore、シンガポール、117549
- Novartis Investigative Site
-
-
-
-
-
Bangkok、タイ、10330
- Novartis Investigative Site
-
Bangkok、タイ、10700
- Novartis Investigative Site
-
Bangkok、タイ、10400
- Novartis Investigative Site
-
Chiang Mai、タイ、50200
- Novartis Investigative Site
-
Muang、タイ、40002
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla、Hat Yai、タイ、90110
- Novartis Investigative Site
-
-
-
-
-
Makati City、フィリピン、1229
- Novartis Investigative Site
-
Manila、フィリピン、1003
- Novartis Investigative Site
-
Pasig City、フィリピン、1605
- Novartis Investigative Site
-
Quezon City、フィリピン、1102
- Novartis Investigative Site
-
Quezon City、フィリピン、1113
- Novartis Investigative Site
-
San Juan City、フィリピン、1500
- Novartis Investigative Site
-
-
Manila
-
Quezon City、Manila、フィリピン、1100
- Novartis Investigative Site
-
-
Metro Manila
-
Manila、Metro Manila、フィリピン、1000
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- Novartis Investigative Site
-
Kuala Lumpur、マレーシア、50400
- Novartis Investigative Site
-
-
MYS
-
Kuala Lumpur、MYS、マレーシア、56000
- Novartis Investigative Site
-
-
Sabah
-
Kota Kinabalu、Sabah、マレーシア、88300
- Novartis Investigative Site
-
-
Sarawak
-
Kuching、Sarawak、マレーシア、94300
- Novartis Investigative Site
-
-
Selangor Darul Ehsan
-
Kuala Lumpur、Selangor Darul Ehsan、マレーシア、43000
- Novartis Investigative Site
-
Sungai Buloh、Selangor Darul Ehsan、マレーシア、47000
- Novartis Investigative Site
-
-
-
-
-
Amman、ヨルダン、11183
- Novartis Investigative Site
-
Amman、ヨルダン、11184
- Novartis Investigative Site
-
-
JOR
-
Amman、JOR、ヨルダン、11152
- Novartis Investigative Site
-
-
-
-
-
Ashrafieh、レバノン、166830
- Novartis Investigative Site
-
Beirut、レバノン、1107 2020
- Novartis Investigative Site
-
Beirut、レバノン
- Novartis Investigative Site
-
Hazmieh、レバノン、470
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100050
- Novartis Investigative Site
-
Chongqing、中国、400037
- Novartis Investigative Site
-
Shanghai City、中国
- Novartis Investigative Site
-
-
Beijing
-
Beijing、Beijing、中国、100039
- Novartis Investigative Site
-
Beijing、Beijing、中国、100037
- Novartis Investigative Site
-
-
Gansu
-
Lanzhou、Gansu、中国、730030
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou、Guangdong、中国、51000
- Novartis Investigative Site
-
Guangzhou、Guangdong、中国、510515
- Novartis Investigative Site
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- Novartis Investigative Site
-
Yangzhou、Jiangsu、中国
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang、Liaoning、中国、110000
- Novartis Investigative Site
-
Shenyang、Liaoning、中国、110003
- Novartis Investigative Site
-
-
Shanghai
-
Jinshan、Shanghai、中国、201508
- Novartis Investigative Site
-
Shanghai、Shanghai、中国、200032
- Novartis Investigative Site
-
-
Shanxi
-
Xian、Shanxi、中国、710061
- Novartis Investigative Site
-
-
Tianjin
-
Tianjin、Tianjin、中国、300121
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310013
- Novartis Investigative Site
-
Wenzhou、Zhejiang、中国、325000
- Novartis Investigative Site
-
-
-
-
-
Changhua、台湾、50006
- Novartis Investigative Site
-
Kaohsiung、台湾、80756
- Novartis Investigative Site
-
Kaohsiung City、台湾、83301
- Novartis Investigative Site
-
New Taipei、台湾、22060
- Novartis Investigative Site
-
Taichung、台湾、40447
- Novartis Investigative Site
-
Taipei、台湾、10002
- Novartis Investigative Site
-
Taipei、台湾、11217
- Novartis Investigative Site
-
Taipei、台湾、10449
- Novartis Investigative Site
-
Taoyuan、台湾、33305
- Novartis Investigative Site
-
Yilan、台湾、26058
- Novartis Investigative Site
-
-
-
-
-
Busan、大韓民国、602739
- Novartis Investigative Site
-
Gwangju、大韓民国、61469
- Novartis Investigative Site
-
Incheon、大韓民国、405 760
- Novartis Investigative Site
-
Seoul、大韓民国、03080
- Novartis Investigative Site
-
Seoul、大韓民国、03722
- Novartis Investigative Site
-
Seoul、大韓民国、02841
- Novartis Investigative Site
-
-
Bucheon Si
-
Gyeonggi do、Bucheon Si、大韓民国、422-711
- Novartis Investigative Site
-
-
Chungcheongbuk Do
-
Cheongju si、Chungcheongbuk Do、大韓民国、28644
- Novartis Investigative Site
-
-
Gangwon-do
-
Wonju、Gangwon-do、大韓民国、26427
- Novartis Investigative Site
-
-
Gyeonggi Do
-
Bundang Gu、Gyeonggi Do、大韓民国、13620
- Novartis Investigative Site
-
-
Korea
-
Seoul、Korea、大韓民国、05505
- Novartis Investigative Site
-
Seoul、Korea、大韓民国、06351
- Novartis Investigative Site
-
Seoul、Korea、大韓民国、08308
- Novartis Investigative Site
-
-
Seocho Gu
-
Seoul、Seocho Gu、大韓民国、06591
- Novartis Investigative Site
-
-
-
-
-
Osaka、日本、534-0021
- Novartis Investigative Site
-
Saitama、日本、330 8503
- Novartis Investigative Site
-
-
Aichi
-
Nagakute-city、Aichi、日本、480-1195
- Novartis Investigative Site
-
Seto-city、Aichi、日本、489-8642
- Novartis Investigative Site
-
-
Chiba
-
Kamogawa-city、Chiba、日本、2968602
- Novartis Investigative Site
-
-
Ehime
-
Saijo-city、Ehime、日本、793-0027
- Novartis Investigative Site
-
-
Fukuka
-
Chikushino-city、Fukuka、日本、818-8516
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka-city、Fukuoka、日本、810-0001
- Novartis Investigative Site
-
Fukuoka-city、Fukuoka、日本、811-0213
- Novartis Investigative Site
-
Fukuoka-city、Fukuoka、日本、815-8588
- Novartis Investigative Site
-
Iizuka-city、Fukuoka、日本、820-8505
- Novartis Investigative Site
-
Kurume-city、Fukuoka、日本、830-8543
- Novartis Investigative Site
-
Kurume-city、Fukuoka、日本、830-8577
- Novartis Investigative Site
-
-
Gifu
-
Ogaki-city、Gifu、日本、503-8502
- Novartis Investigative Site
-
-
Hokkaido
-
Kushiro-city、Hokkaido、日本、085-0062
- Novartis Investigative Site
-
Sapporo-city、Hokkaido、日本、006-8555
- Novartis Investigative Site
-
-
Hyogo
-
Amagasaki city、Hyogo、日本、660 8550
- Novartis Investigative Site
-
Kobe-City、Hyogo、日本、654-0155
- Novartis Investigative Site
-
-
Ibaraki
-
Mito-city、Ibaraki、日本、311-4198
- Novartis Investigative Site
-
-
Ishikawa
-
Kanazawa、Ishikawa、日本、920 8650
- Novartis Investigative Site
-
-
Kagawa
-
Kanonji-city、Kagawa、日本、769-1695
- Novartis Investigative Site
-
Takamatsu city、Kagawa、日本、760 8557
- Novartis Investigative Site
-
-
Kanagawa
-
Kawasaki-city、Kanagawa、日本、211-8533
- Novartis Investigative Site
-
Yokohama city、Kanagawa、日本、232 0024
- Novartis Investigative Site
-
Yokohama-city、Kanagawa、日本、236 0051
- Novartis Investigative Site
-
Yokohama-city、Kanagawa、日本、227-8501
- Novartis Investigative Site
-
Yokohama-city、Kanagawa、日本、231-8682
- Novartis Investigative Site
-
-
Kochi
-
Kochi city、Kochi、日本、781 8555
- Novartis Investigative Site
-
-
Kumamoto
-
Kumamoto-city、Kumamoto、日本、861-4193
- Novartis Investigative Site
-
Yatsushiro-city、Kumamoto、日本、866-8660
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto-city、Kyoto、日本、607-8062
- Novartis Investigative Site
-
Uji-city、Kyoto、日本、611-0042
- Novartis Investigative Site
-
-
Miyagi
-
Sendai-city、Miyagi、日本、981-3133
- Novartis Investigative Site
-
-
Nagano
-
Nakano-city、Nagano、日本、383-8505
- Novartis Investigative Site
-
Saku-city、Nagano、日本、3850051
- Novartis Investigative Site
-
Ueda-city、Nagano、日本、386-8610
- Novartis Investigative Site
-
-
Niigata
-
Niigata-city、Niigata、日本、950-1197
- Novartis Investigative Site
-
-
Osaka
-
Osaka-city、Osaka、日本、540-0006
- Novartis Investigative Site
-
-
Saitama
-
Kawaguchi-city、Saitama、日本、333-0842
- Novartis Investigative Site
-
Sayama-city、Saitama、日本、350-1323
- Novartis Investigative Site
-
Wako-city、Saitama、日本、351-0102
- Novartis Investigative Site
-
-
Shiga
-
Kusatsu city、Shiga、日本、525 8585
- Novartis Investigative Site
-
-
Shizuoka
-
Hamamatsu-city、Shizuoka、日本、430-8558
- Novartis Investigative Site
-
Kakegawa-city、Shizuoka、日本、436-8555
- Novartis Investigative Site
-
-
Tokyo
-
Akishima-city、Tokyo、日本、196-0003
- Novartis Investigative Site
-
Chuo ku、Tokyo、日本、104-8560
- Novartis Investigative Site
-
Hachioji-city、Tokyo、日本、192-0918
- Novartis Investigative Site
-
Itabashi-ku、Tokyo、日本、173-8610
- Novartis Investigative Site
-
Musashino-city、Tokyo、日本、180-8610
- Novartis Investigative Site
-
Shinagawa ku、Tokyo、日本、141 8625
- Novartis Investigative Site
-
Shinagawa-ku、Tokyo、日本、142-8666
- Novartis Investigative Site
-
-
Wakayama
-
Tanabe-city、Wakayama、日本、646-8558
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female ≥ 18 years of age, with body weight ≤160 kg
Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:
- Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
- Pulmonary congestion on chest radiograph
- Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
- Systolic BP ≥125 mmHg at the start and at the end of screening
- Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
- Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
- Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).
Exclusion Criteria:
- Dyspnea primarily due to non-cardiac causes
- Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).
Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment
*Patients with systolic blood pressure >180 mmHg at the end of screening
- AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute
Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).
*Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
|
静脈内注入
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
|
実験的:Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
|
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
点滴静注
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
時間枠:through day 5
|
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change.
Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
|
through day 5
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Time to WHF
時間枠:Through Day 5
|
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
|
Through Day 5
|
Time to CV Death
時間枠:Through Day 180
|
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
|
Through Day 180
|
Time to All-cause Death
時間枠:Through Day 180
|
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
|
Through Day 180
|
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
時間枠:Through Day 5
|
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
|
Through Day 5
|
Dyspnea by VAS-AUC Changes
時間枠:Through Day 5
|
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
|
Through Day 5
|
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
時間枠:Up to day 30
|
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
|
Up to day 30
|
Renal Dysfunction and Prevention of Worsening of Renal Function
時間枠:Through Day 5
|
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
|
Through Day 5
|
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
時間枠:Through Day 180
|
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
|
Through Day 180
|
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
時間枠:Through Day 180
|
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
|
Through Day 180
|
Time to In-hospital Worsening Heart Failure Through Day 5
時間枠:Through Day 5
|
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe).
In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
|
Through Day 5
|
Use of Loop Diuretic and Vasoactive Agents
時間枠:Through Day 5
|
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
|
Through Day 5
|
Change From Baseline in Cardio-renal Biomarkers
時間枠:Day 2 and Day 5
|
Day 2 and Day 5
|
|
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
時間枠:For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
|
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
|
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, Lopez-Sendon J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circ Heart Fail. 2022 Apr;15(4):e009199. doi: 10.1161/CIRCHEARTFAILURE.121.009199. Epub 2022 Feb 21.
- Grand J, Miger K, Sajadieh A, Køber L, Torp-Pedersen C, Ertl G, López-Sendón J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. J Am Heart Assoc. 2021 Sep 21;10(18):e022288. doi: 10.1161/JAHA.121.022288. Epub 2021 Sep 13.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CRLX030A2302
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
急性心不全の臨床試験
-
Novartis Pharmaceuticals完了EC-MPS による治療に関心があり、コア研究の 12 か月の治療期間を無事に完了した患者 (de novo Heart Recipients)
プラセボの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない